IJEMD-BMCR, 3 (1) (2025) https://doi.org/ 10.54938/ijemdbmcr.2025.03.1.416

International Journal of Emerging Multidisciplinaries:
Biomedical and Clinical Research

Research Paper
Journal Homepage: www.ojs.ijemd.com
ISSN (print): 2957-8620 ISSN (online): 2960-0731

Diagnosis, Treatment and Future Perspectives in Artificial Intelligence and Neuronal Diseases

Sara Raouf [1] , Diar Raouf [1] , Lana Raouf [1] , Eda Alemdar [1]*

1. V N Karazin Kharkiv National Medical University, Ukraine.

Abstract

This article focuses on the role of Artificial Intelligence in the diagnosis and treatment of neuronal diseases and future perspectives on the subject. Neuronal diseases involve complex pathophysiological processes that affect the central and peripheral nervous systems. They can cause permanent damage to the cognitive, motor and sensory functions of individuals. Notable Diseases such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS) are characterized by degeneration of nerve cells, neuroinflammation and neurotransmitter imbalances. Early diagnosis of neuronal diseases is of critical importance in slowing down the progression of the disease, controlling symptoms and improving the quality of life of patients. However, one of the biggest challenges in the diagnosis of these diseases is that symptoms usually appear in the advanced stages of the disease process. In recent years, artificial intelligence (AI)-supported technologies have made great progress in the diagnosis of neurological diseases. Artificial intelligence can analyze biomarkers in blood, cerebrospinal fluid or saliva to detect the disease in its early stages. By processing this data with deep learning techniques, artificial intelligence can detect disease symptoms at early stages and support personalized diagnosis and treatment processes. Electrophysiological data analysis also plays an important role in the diagnosis of neurological diseases. Artificial intelligence algorithms can detect abnormal brain activities by processing EEG (electroencephalography) and MEG (magnetoencephalography) data. For example, in epilepsy patients, seizures can be predicted before they start using machine learning, while in dementia patients, changes in brain waves can be detected at an early stage. Artificial intelligence can learn how disease symptoms change in different individuals

Email Addresses: sararaouf646@gmail.com (Sara) , Ddiar@live.de (Diar) , Lana_raouf@hotmail.com (Lana) , alemdar.neuralpress@gmail.com (Eda)

by analyzing a lot of patient data from around the world. While this process allows machine learning models to make more precise and reliable diagnoses, systems developed on the basis of Dr. Roman Poznanski's DOT (Dynamic Optimization of Thought) theory offer a new method in the diagnosis of neurological diseases. Artificial intelligence has become an effective tool in slowing down the progression of neurological diseases by optimizing patients' individualized treatment plans. In the future, it will be possible to develop more integrated and dynamic solutions for the diagnosis, monitoring and treatment of neurological diseases thanks to DOT theory and conscious artificial intelligence models. These systems will analyze brain functions not only through biological data but also in the context of energy flows and information processing processes, providing personalized, optimized and preventive approaches.

***Keywords*:** Artificial Intelligence, Diagnosis and Treatment, Neuronal Diseases, Dynamic Optimization of Thought DOT.

1. Introduction

Neuronal diseases involve complex pathophysiological processes that can affect the central and peripheral nervous system, leading to permanent damage to individuals' cognitive, motor and sensory functions [2] , [13]. Diseases such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS) are characterized by degeneration of nerve cells, neuroinflammation and neurotransmitter imbalances. These diseases are progressive, often irreversible disorders that severely impact individuals' quality of life and require early diagnosis and effective treatment strategies.

Traditional diagnostic methods include clinical assessment, biomarker analysis, neuroimaging techniques such as magnetic resonance imaging (MRI) and electroencephalography (EEG) [3]. However, these methods are not always conclusive and can be difficult to diagnose in the early stages of the disease. Moreover, current treatment approaches often focus on managing symptoms but fall short of halting disease progression or promoting nerve cell regeneration. Therefore, more advanced diagnostic and therapeutic methods are needed in the fight against neurodegenerative diseases.

In recent years, the innovations offered by artificial intelligence (AI) technologies in the biomedical field offer promising developments in the understanding, early diagnosis and management of neurological diseases [15]. Thanks to big data analytics, machine learning and deep learning algorithms, it has become possible to analyze multidimensional data on diseases to identify biomarkers, develop clinical decision support systems and create individualized treatment approaches.

By processing large-scale clinical and genetic data, AI-based systems can enable better modeling of neurodegenerative processes and deeper understanding of disease mechanisms.

In this article, we will discuss the current and potential applications of artificial intelligence in the diagnosis, monitoring and treatment of neuronal diseases. In particular, we will evaluate the effectiveness of artificial intelligence solutions in areas such as neurological imaging, biomarker analysis, personalized treatment plans and disease prediction models and discuss future research directions.

2. Artificial Intelligence and Diagnosis of Neuronal Diseases

Early diagnosis of neuronal diseases is critical to slow disease progression, control symptoms and improve patients' quality of life [7]. However, one of the biggest challenges in diagnosing these diseases is that symptoms often appear later in the disease process. For example, Alzheimer's disease is often diagnosed after patients have developed severe cognitive impairments, whereas in Parkinson's disease, a large proportion of dopaminergic neurons may be damaged before motor symptoms appear. Therefore, the development of early detection methods is a major necessity in the fight against neurodegenerative diseases.

Traditional diagnostic methods are based on patient-reported symptoms, clinical examinations and subjective assessments by doctors [5]. Techniques such as magnetic resonance imaging (MRI), positron emission tomography (PET), electroencephalography (EEG) and cerebrospinal fluid (CSF) analysis can help identify biological signs of the disease. However, these methods are often costly, time-consuming and in some cases have limited sensitivity and may not be effective enough for early diagnosis.

In recent years, artificial intelligence (AI)-enabled technologies have enabled major advances in the diagnosis of neurological diseases. Using approaches such as big data analytics, machine learning (ML) and deep learning (DL), AI processes information from biomarker analyses, advanced brain imaging techniques, genetic data and behavioral analyses, enabling earlier, faster and more objective diagnosis.

3. Artificial Intelligence Supported Diagnostic Methods

3.1. Biomarker Analysis

By analyzing biomarkers in blood, cerebrospinal fluid or saliva, AI can detect disease in its early stages [1]. For example, in Alzheimer's disease, analyzing amyloid beta and tau protein levels with AI algorithms can help predict the onset of the disease years in advance, or in Parkinson's disease, AI modeling of specific proteins or cellular metabolites in the blood can facilitate the diagnosis of the disease.

3.2. Imaging Techniques and Artificial Intelligence

Methods such as advanced brain imaging techniques, speech and behavioral analysis, electrophysiological data analysis and genetic sequence analysis are becoming increasingly important in the diagnosis of neuronal diseases. By processing this data with deep learning techniques, artificial intelligence can detect disease symptoms at early stages and support personalized diagnosis and treatment processes.

Imaging modalities such as MRI and PET can detect shrinkage in the hippocampus and changes in brain tissue in Alzheimer's patients in the early stages, while in Parkinson's patients, the progression of the disease can be monitored by modeling brain activity changes caused by the loss of dopaminergic neurons [14]. AI-assisted retinal screening systems have the potential to detect vascular changes associated with these diseases.

In addition, neurological diseases can lead to early changes in speech patterns, motor skills and cognitive functions. AI- powered voice analysis and behavioral monitoring systems can make early diagnoses by analyzing changes in speech fluency, word choice and sentence structure in Alzheimer's patients. In Parkinson's patients, the progression of the disease can be monitored by analyzing biometric data such as facial expression, walking patterns and fine motor movements.

Electrophysiological data analysis also plays an important role in the diagnosis of neurological diseases. Artificial intelligence algorithms can detect abnormal brain activity by processing EEG (electroencephalography) and MEG (magnetoencephalography) data [20]. For example, in epilepsy patients, machine learning can be used to predict seizures before they start, while in dementia patients, changes in brain waves can be detected at an early stage.

Genetic predisposition is also a determining factor in the development of neurological diseases. Artificial intelligence can identify individuals' susceptibility to diseases such as Alzheimer's, Parkinson's or ALS through genetic sequence analysis. [4] , [22]. By analyzing patients' genetic mutations, machine learning algorithms can identify risk groups and provide more effective health management by creating personalized treatment plans.

One of the biggest advantages that artificial intelligence offers to the diagnostic process is the early detection of diseases. It offers the possibility to slow down the progression of the disease by detecting biological changes before symptoms. It can also provide higher accuracy rates compared to traditional methods, enabling more precise and objective analysis. Artificial intelligence can create personalized diagnosis and treatment strategies by combining genetic, biological and clinical data. In addition, it can quickly process large data sets, saving doctors time and making the diagnostic process more efficient. This enables earlier and more effective interventions in the management of neurological diseases.

Artificial intelligence has a significant potential in the early diagnosis of neuronal diseases [18] , [8]. Artificial intelligence- supported systems in areas such as biomarker analysis, advanced imaging techniques, evaluation of genetic data and behavioral analysis enable both more accurate and faster diagnosis. In addition to improving the quality of life of patients, these technologies can offer a more effective treatment process by reducing the burden on healthcare systems. However, more clinical validation and ethical regulations are needed for AI-based diagnostic systems to become widespread. In the future, great advances are expected to be made in the diagnosis and management of neurological diseases with the increased use of AI-enabled systems in clinical practice.

3.3. Improving Diagnosis Process with Big Data and Machine Learning

By analyzing patient data from around the world, artificial intelligence can learn how disease symptoms change in different individuals. While this process enables machine learning models to make more precise and reliable diagnoses, systems developed on the basis of Roman Poznanski's DOT (Dynamic Optimization of Thought) theory offer a new method for diagnosing neurological diseases [19]. DOT theory suggests that the flow of information in conscious systems is not only through neural networks, but also through energy transformations and information optimization. In this context, artificial intelligence can not only analyze data in the diagnosis of neuronal diseases, but also model energy transfers and optimization processes in brain functioning, allowing for a deeper understanding of early signs of diseases.

Artificial intelligence systems based on DOT theory evaluate the development of neurological diseases by combining biomarker analysis, advanced imaging techniques and speech motor skill analysis. For example, in Alzheimer's disease, it can detect structural changes in the hippocampus as well as disruptions in the brain's energy optimization. In Parkinson's patients, by analyzing the disruptions in energy transfers associated with the loss of dopaminergic neurons, it can more precisely track the progression of the disease. By identifying changes in these energy and information flows at an early stage, AI-enabled systems enable the development of personalized treatment protocols.

In this context, DOT machines, based on Poznanski's theory, make it possible to treat brainwaves not only as electrical signals but also in the context of information and energy optimization. By evaluating

EEG and MEG data, it not only identifies abnormal brain activities related to neurological diseases, but also analyzes the effects of these activities on energy dynamics. For example, it can detect irregularities in energy flow before the onset of seizures in epilepsy patients and use this information to predict seizures in advance.

In addition, systems based on DOT theory can determine the susceptibility of individuals to neurodegenerative diseases through big data analyses and examine how genetic mutations change not only in static but also in dynamic processes. Thus, by going one step ahead of traditional artificial intelligence models, it is possible to understand the neurological evolution of the individual over time and the disease development process much more precisely.

The combination of artificial intelligence and DOT theory offers an important approach to the diagnosis of neurological diseases. These systems, which combine different techniques such as biomarker analysis, advanced imaging methods, speech and motion analysis, make it possible to diagnose neurodegenerative diseases in the early stages and provide patients with more effective and individualized treatment. In the future, with the widespread use of these systems, we envision earlier diagnosis of neurological diseases and the development of treatment strategies that will preserve patients' cognitive functions in the long term.

4. Artificial Intelligence Assisted Treatment Methods

Artificial intelligence has become an effective tool in slowing the progression of neurological diseases by optimizing individualized treatment plans for patients. Thanks to big data analytics and machine learning techniques, patients' genetic makeup, clinical history and biomarkers are evaluated to develop personalized treatment strategies [11] , [21]. Especially for Alzheimer's and Parkinson's diseases, artificial intelligence can predict the effectiveness of certain drugs on individual patients by analyzing pharmacogenetic data [6]. It can also offer targeted therapies by identifying changes at the cellular level in neurodegenerative diseases, thus enabling the most appropriate treatment option for each patient.

Brain computer interfaces (BCIs) are an important technology that increases the impact of artificial intelligence on neurological diseases. These systems have the potential to restore mobility to patients who have lost motor skills by directly intervening in the nervous system. Especially for ALS patients, AI-based BCI systems can help patients regain their ability to communicate and move by interpreting brain signals. In Parkinson's patients, AI-supported deep brain stimulation (DBS) algorithms can analyze abnormal electrical activity in the brain and provide more precise application of stimulation.

Artificial intelligence also offers great advantages in the monitoring and prevention of neurological diseases [15] , [16]. Thanks to smart sensors and mobile applications, the motor movements of Parkinson's patients can be tracked in real time, providing data to doctors about the progression of the disease [17] , [9]. In epilepsy patients, deep learning models can analyze EEG signals to predict the likelihood of seizures and create a chance for early intervention. Artificial intelligence can also contribute to the development of strategies for early diagnosis and prevention of diseases such as Alzheimer's by analyzing the relationship between sleep patterns and cognitive functions.

The use of artificial intelligence in research and clinical applications related to neuronal diseases is becoming increasingly widespread. However, the ethical and legal aspects of this technology should also be considered. While data security requires the protection of patients' genetic and medical information, ethical rules should be determined on how to integrate artificial intelligence into clinical decision-making mechanisms. In addition, it is important that personalized treatment methods are offered equally to all patient groups and are not accessible only to a certain segment.

Conscious artificial intelligence based on DOT theory aims to develop these systems in a way that optimizes brain energy, not just mechanical commands. In this way, unlike traditional systems, self-optimizing interfaces can be created that adapt to the individual brain wave patterns of patients.

The management of neurological diseases is not only limited to diagnosis and treatment, but also includes preventive approaches. Aware AI-powered sensors and mobile systems can contribute to early disease prevention by tracking individual energy consumption dynamics and micro changes in neurological functions [23].

5. Final reflections

In the future, the DOT theory and conscious artificial intelligence models will enable the development of more integrated and dynamic solutions for the diagnosis, monitoring and treatment of neurological diseases. These systems will offer personalized, optimized and preventive approaches by analyzing brain functions not only through biological data but also in the context of energy flows and information processing processes.

This new approach will improve the early diagnosis and individualized treatment of neurological diseases and will contribute to our understanding of the fundamental principles of brain functioning.

References

[1] Adeoye, J. & Su, Y.-X. (2024) Artificial intelligence in salivary biomarker discovery and validation for oral diseases. *Oral Diseases*, **30**, 23–37. https://doi. org/10.1111/odi.14641.

[2] Ayeni, E. A. & Aldossary, A. M. & Ayejoto, D. A. & Gbadegesin, L. A. & Alshehri, A. A.

& Alfassam, H. A. & Afewerky, H. K. & Almughem, F. A. & Bello, S. M. & Tawfik, E. A. (2022) Neurodegenerative Diseases: Implications of Environmental and Climatic Influences on Neurotransmitters and Neuronal Hormones Activities. *Int J Environ Res Public Health*, **19**(19), 12495. doi: 10.3390/ijerph191912495.

[3] Bandopadhyay, R. & Singh, T. & Ghoneim, M. M. & Alshehri, S. & Angelopoulou, E. & Paudel, Y. N. & Piperi, C. & Ahmad, J. & Alhakamy, N. A. & Alfaleh, M. A. & Mishra, A. (2021) Recent Developments in Diagnosis of Epilepsy: Scope of MicroRNA and Technological Advancements. *Biology* (Basel). **10**(11), 1097. doi: 10.3390/biology10111097.

[4] Bettencourt, C. & Skene, N.& Bandres-Ciga, S. & Anderson, E. & Winchester, L.M. & Foote, I.F. & Schwartzentruber, J. & Botia, J.A. & Nalls, M. & Singleton, A. & Schilder, B.M. & Humphrey, J. & Marzi, S.J. 6 Toomey, C.E. & Kleifat, A. A. & Harshfield, E. L. & Garfield, V. & Sandor, C. & Keat, S. & Tamburin, S. & Frigerio, C.S. & Lourida, I. (2023) Artificial intelligence for dementia genetics and omics. *Alzheimers Dement*, **12**, 5905-5921. doi: 10.1002/alz.13427.

[5] Committee on Diagnostic Error in Health Care; Board on Health Care Services; Institute of Medicine; The National Academies of Sciences, Engineering, and Medicine. (2015) Balogh, E.P, Miller, B.T, Ball, J.R, editors. *Improving Diagnosis in Health Care*. Washington (DC): National Academies Press (US); The Diagnostic Process. Available from: https://www.ncbi.nlm.nih.gov/books/NBK338593/.

[6] Crews, K. R. & Hicks, J.K. & Pui, C.H. & Relling, M.V. & Evans, W.E. (2012) Pharmacogenomics and individualized medicine: translating science into practice. *Clin Pharmacol Ther*. **92**(4), 467-75. doi: 10.1038/clpt.2012.120.

[7] Di Luca, M. & Nutt, D. & Oertel, W. & Boyer, P. & Jaarsma, J. & Destrebecq, F. & Esposito, G. & Quoidbach, V. (2018) Towards earlier diagnosis and treatment of disorders of the brain. *Bull World Health Organ*. **96**(5), 298-298A. doi: 10.2471/BLT.17.206599.

[8] El-Sayed, M. & El-kenawy. (2024) Application of Artificial Intelligence in Early Diagnosis of Neurodegenerative Diseases. *Metaheuristic Optimization Review*, **1** (2), 22-36. doi: https://doi.org/10.54216/MOR.010203.

[9] Espay, A.J. & Bonato, P.& Nahab, F.B. & Maetzler, W. & Dean, J. M. & Klucken, J. & Eskofier, B. M. & Merola, A. & Horak, F. & Lang, A.E. & Reilmann, R. & Giuffrida, J. & Nieuwboer, A. & Horne, M. & Little, M. A. & Litvan, I. & Simuni, T. & Dorsey, E.R. & Burack, M.A. & Kubota, K. & Kamondi, A. & Godinho, C. & Daneault, J. F. & Mitsi, G. & Krinke, L. & Hausdorff, J.M. & Bloem, B.R. & Papapetropoulos, S. (2016) Movement Disorders Society Task Force on Technology. Technology in Parkinson's disease: Challenges and opportunities. *Mov Disord*. **31**(9), 1272-82. doi: 10.1002/mds.26642.

[10] Harishbhai, Tilala M. & Kumar, Chenchala P. & Choppadandi, A. & Kaur, J. & Naguri, S. & Saoji, R. & Devaguptapu, B. (2024) Ethical Considerations in the Use of Artificial Intelligence and Machine Learning in Health Care: A Comprehensive Review. *Cureus*. **16**(6), e62443. doi: 10.7759/cureus.62443.

[11] Hassan, M. & Awan, F. M. & Naz, A. & deAndrés-Galiana, E. J. & Alvarez, O. & Cernea, A. & Fernández-Brillet, L. & Fernández-Martínez, J. L. & Kloczkowski, A. (2022) Innovations in Genomics and Big Data Analytics for Personalized Medicine and Health Care:

A Review. *Int J Mol Sci* **23**(9), 4645. doi: 10.3390/ijms23094645.

[12] Hippman C. & Nislow, C. (2019) Pharmacogenomic Testing: Clinical Evidence and Implementation Challenges. *J Pers Med*. **9**(3), 40. doi: 10.3390/jpm9030040.

[13] Hutton J. L. (2002) Pharoah PODEffects of cognitive, motor, and sensory disabilities on survival in cerebral palsy. *Archives of Disease in Childhood*, **86**, 84-89.

[14] Johnson, K.A. & Fox, N. C. & Sperling, R. A. & Klunk, W.E. (2012) Brain imaging in Alzheimer disease. *Cold Spring Harb Perspect Med*. **4**, a006213. doi: 10.1101/cshperspect.a006213.

[15] Kalani, M. & Anjankar A. (2024) Revolutionizing Neurology: The Role of Artificial Intelligence in Advancing Diagnosis and Treatment. *Cureus* **16**(6), e61706. doi: 10.7759/cureus.61706.

[16] Khalifa, M. & Albadawy, M. (2024) Artificial Intelligence for Clinical Prediction: Exploring Key Domains and Essential Functions. *Computer Methods and Programs in Biomedicine Update*, **5.** https://doi.org/10.1016/j.cmpbup.2024.100148.

[17] Moreau, C. & Rouaud, T. & Grabli, D. et al. (2023). Overview on wearable sensors for the management of Parkinson’s disease. *Nature npj Parkinsons Dis*. **9**, 153. https://doi.org/10.1038/s41531-023-00585-y.

[18] Potter, K. & Doris, L. (2024). Application of Artificial Intelligence in Early Diagnosis of Neurodegenerative Diseases.

[19] Poznanski, Roman R. (2024). Some necessary constructs of consciousness as defined in the dynamic organicity theory. *Journal of Multiscale Neuroscience*, **3**(2), 98-108.

[20] Shang, S. & Shi, Y. & Zhang, Y. & Liu, M. & Zhang, H. & Wang, P. & Zhuang, L. (2024) Artificial intelligence for brain disease diagnosis using electroencephalogram signals. *J Zhejiang Univ Sci B.* **25**(10), 914-940. doi: 10.1631/jzus.B2400103.

[21] Taherdoost, H. & Ghofrani, A. (2024). AI's role in revolutionizing personalized medicine by reshaping pharmacogenomics and drug therapy. *Intelligent Pharmacy*, **2**(5), 643-650.

[22] Winchester, L.M. & Harshfield, E.L. & Shi, L. & Badhwar, A. & Khleifat, A.A. & Clarke, N. & Dehsarvi, A. & Lengyel, I. & Lourida, I. & Madan, C.R. & Marzi, S.J. & Proitsi, P. & Rajkumar, A. P. & Rittman, T. & Silajdžić, E. & Tamburin, S. & Ranson, J. M. & Llewellyn, D.J. (2023) Artificial intelligence for biomarker discovery in Alzheimer's disease and dementia. *Alzheimers Dement*. **12**, 5860-5871. doi: 10.1002/alz.13390.

[23] Yammouri, G. & Lahcen, A. A. (2024). AI-Reinforced Wearable Sensors and Intelligent Point-of-Care Tests. *J. Pers. Med*. **14** (11), 1088. https://doi.org/10.3390/jpm14111088.